| Literature DB >> 30662525 |
Ke Shi1,2, Na Li3, Meilan Yang3, Wei Li1,2.
Abstract
Smoking is considered the major risk factor for lung cancer, but only a small portion of female lung adenocarcinoma patients are associated with smoking. Thus, identifying crucial genes and pathways related to nonsmoking female lung cancer patients is of great importance. Gene expression profiles were downloaded from the Gene Expression Omnibus (GEO) and the Cancer Genome Atlas (TCGA) databases. The R software packages were applied to screen the differentially expressed genes (DEGs). GO term enrichment and KEGG pathway analyses were carried out using DAVID tools. The protein-protein interaction (PPI) network was constructed by Cytoscape software. In total, 487 downregulated and 199 upregulated DEGs were identified. The down-regulated DEGs were mainly enriched for behavior and response to wounding, and the upregulated DEGs were significantly enriched for multicellular organismal metabolic process and cell division. The KEGG pathway analysis revealed that the downregulated DEGs were significantly enriched for cell adhesion molecules and neuroactive ligand-receptor interaction, while the upregulated DEGs were mainly enriched for cell cycle and the p53 signaling pathway. The top 10 hub genes and top 3 gene interaction modules were selected from the PPI network. Of the ten hub genes, a high expression of five genes was related to a poor OS in female lung cancer patients who never smoked, including IL6, CXCR2, FPR2, PPBP and HBA1. However, a low expression of GNG11, LRRK2, CDH5, CAV1 and SELE was associated with a worse OS for the female lung cancer patients who never smoked. In conclusion, our study provides novel insight for a better understanding of the pathogenesis of nonsmoking female lung cancer, and these identified DEGs may serve as biomarkers for diagnostics and treatment.Entities:
Keywords: bioinformatics; female lung cancer; hub genes; never smoking
Year: 2019 PMID: 30662525 PMCID: PMC6329865 DOI: 10.7150/jca.26908
Source DB: PubMed Journal: J Cancer ISSN: 1837-9664 Impact factor: 4.207
Figure 1Volcano plot of 2844 differentially expressed genes. Red: up-regulation with fold change of more than 2; green: down-regulation with a fold change of more than 2; blue: unchanged genes.
Figure 2Heatmap of the top 100 differentially expressed genes with a fold change of more than 2. Red: up-regulation; green: down-regulation.
Figure 3Gene ontology and KEGG pathway analyses results of the down-regulated differentially expressed genes with a fold change of more than 2. BP: biological process; CC: cellular component; MF: molecular function.
Figure 4Gene ontology and KEGG pathway analyses results of the up-regulated differentially expressed genes with a fold change of more than 2. BP: biological process; CC: cellular component; MF: molecular function.
Figure 5Module analysis of the PPI network. (a): module 1; (b): GO analysis of module 1; (c): module 2; (d): GO analysis of module 2; (e): module 3; (f): GO analysis of module 3.
Prognostic value of the ten hub genes in the female lung cancer patients who never smoked.
| Gene name | HR with 95% CI | |
|---|---|---|
| IL6 | 2.5(1.32, 4.73) | 3.5 e-03 |
| GNG11 | 0.49(0.25,0.98) | 0.038 |
| CXCR2 | 3.38(1.2-9.54) | 0.015 |
| LRRK2 | 0.24(0.08-0.72) | 5.5e-03 |
| CDH5 | 0.28(0.15-0.54) | 3.5e-05 |
| FPR2 | 2.56(1.36-4.82) | 2.5e-03 |
| PPBP | 2.12(1.11-4.02) | 0.02 |
| CAV1 | 0.22(0.09-0.52) | 1.6e-04 |
| HBA1 | 2.19(1.16-4.15) | 0.014 |
| SELE | 0.34(0.18-0.65) | 6e-04 |
HR: Hazard ratio; CI: Confidence interval.
Figure 6Prognostic value of four genes in female lung cancer patients. Prognostic value of CDH5(A), HBA1(C), LRRK2(E), and PPBP(G) in female lung cancer patients who never smoked. Prognostic value of CDH5(B), HBA1(D), LRRK2(F), and PPBP(H) in smoking female lung cancer patients.